JP2020531524A5 - - Google Patents

Download PDF

Info

Publication number
JP2020531524A5
JP2020531524A5 JP2020511314A JP2020511314A JP2020531524A5 JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5 JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020511314 A JP2020511314 A JP 2020511314A JP 2020531524 A5 JP2020531524 A5 JP 2020531524A5
Authority
JP
Japan
Prior art keywords
her2
mva
cancer
cells
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020511314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020531524A (ja
JP7202362B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/072789 external-priority patent/WO2019038388A1/en
Publication of JP2020531524A publication Critical patent/JP2020531524A/ja
Publication of JP2020531524A5 publication Critical patent/JP2020531524A5/ja
Application granted granted Critical
Publication of JP7202362B2 publication Critical patent/JP7202362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020511314A 2017-08-24 2018-08-23 組み換えmva及び抗体の静脈内投与を用いた、がん治療のための併用療法 Active JP7202362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17187824 2017-08-24
EP17187824.2 2017-08-24
PCT/EP2018/072789 WO2019038388A1 (en) 2017-08-24 2018-08-23 POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY

Publications (3)

Publication Number Publication Date
JP2020531524A JP2020531524A (ja) 2020-11-05
JP2020531524A5 true JP2020531524A5 (cg-RX-API-DMAC7.html) 2022-09-07
JP7202362B2 JP7202362B2 (ja) 2023-01-11

Family

ID=59702586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020511314A Active JP7202362B2 (ja) 2017-08-24 2018-08-23 組み換えmva及び抗体の静脈内投与を用いた、がん治療のための併用療法

Country Status (12)

Country Link
US (2) US11273211B2 (cg-RX-API-DMAC7.html)
EP (1) EP3691675A1 (cg-RX-API-DMAC7.html)
JP (1) JP7202362B2 (cg-RX-API-DMAC7.html)
KR (1) KR102754876B1 (cg-RX-API-DMAC7.html)
CN (1) CN111050790B (cg-RX-API-DMAC7.html)
AU (1) AU2018320417B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020003669A2 (cg-RX-API-DMAC7.html)
CA (1) CA3073310A1 (cg-RX-API-DMAC7.html)
IL (1) IL272546B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020001856A (cg-RX-API-DMAC7.html)
SG (1) SG11202001115TA (cg-RX-API-DMAC7.html)
WO (1) WO2019038388A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
BR112022009798A2 (pt) * 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
JP7670705B2 (ja) * 2019-11-20 2025-04-30 バヴァリアン・ノルディック・アクティーゼルスカブ 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用
AU2021252164B2 (en) 2020-04-09 2026-07-02 Finncure Oy Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
US12194157B2 (en) 2020-04-09 2025-01-14 Finncure Oy Carrier for targeted delivery to a host
AU2021294322A1 (en) * 2020-06-26 2023-02-02 National Breast Cancer Coalition Breast cancer vaccine
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20240182568A1 (en) * 2021-03-10 2024-06-06 University Of Iowa Research Foundation Methods of enhancing antibody therapies
US20240226233A1 (en) * 2021-05-03 2024-07-11 L&C Bio Co., Ltd. Composition comprising zag-derived peptide for improving scars and keloids

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766598A (en) 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
EP0954593A1 (en) 1996-07-25 1999-11-10 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP1865065A1 (en) * 1998-12-09 2007-12-12 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services A recombinant vector expressing multiple costimulatory molecules and uses thereof
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
DE60235041D1 (de) 2001-11-30 2010-02-25 Us Gov Health & Human Serv Und ihre verwendung
EP1456230A2 (en) 2001-12-04 2004-09-15 Bavarian Nordic A/S Flavivirus ns1 subunit vaccine
EP1649020B1 (en) 2003-07-21 2017-01-11 MSD Italia S.r.l. Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
CA2741724C (en) 2008-11-27 2016-10-04 Bavarian Nordic A/S Promoters for recombinant viral expression
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
ES2660597T3 (es) * 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
US10111946B2 (en) 2012-06-22 2018-10-30 Bavarian Nordic A/S Poxviral vectors for low antibody response after a first priming immunization
EP2892549A1 (en) * 2012-09-04 2015-07-15 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014043518A1 (en) * 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
EP2908851A1 (en) 2012-10-19 2015-08-26 Bavarian Nordic Inc. Methods and compositions for the treatment of cancer
MX380483B (es) 2012-10-28 2025-03-12 Bavarian Nordic As Promotor pr13.5 para respuestas de anticuerpos y linfocitos t fuertes.
US9725494B2 (en) * 2013-05-17 2017-08-08 United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble CD27 (sCD27) and the use thereof
JP6535337B2 (ja) 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び/またはアゴニストにより癌を治療するための組み合わせ療法
ES2895977T3 (es) * 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
DK3142690T3 (da) * 2014-05-13 2022-05-09 Bavarian Nordic As Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist
US20170196953A1 (en) 2014-07-07 2017-07-13 Duke University VACCINES AGAINST AN ONCOGENIC ISOFORM OF HER2 (ErbB2) AND METHODS OF USING THE SAME
CA2960087C (en) * 2014-09-26 2024-02-27 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
DK3329016T3 (da) 2015-07-31 2022-01-10 Bavarian Nordic As Promotorer til forbedring af ekspression i poxvirus
JP7625518B2 (ja) * 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ 4-1bbl(cd137l)及び/またはcd40lをコードする組み換えmvaの腫瘍内及び/または静脈内投与によって、がんを治療する療法
JP7670705B2 (ja) * 2019-11-20 2025-04-30 バヴァリアン・ノルディック・アクティーゼルスカブ 4-1bblアジュバント添加した組み換え改変ワクシニアウイルスアンカラ(mva)の医学的使用
WO2023118508A1 (en) * 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer

Similar Documents

Publication Publication Date Title
US11723964B2 (en) Combination therapy for treating cancer with an antibody and intravenous administration of a recombinant MVA
AU2019385665B2 (en) Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-ibbl (cd137l) and/or cd40l
JP7555334B2 (ja) 組み換えmva、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
JP7644111B2 (ja) がんを治療するための腫瘍内及び/または静脈内投与用組み換えmvaウイルス
EP4452305A1 (en) Recombinant mva viruses for intraperitoneal administration for treating cancer
US20250002606A1 (en) Combination Therapy for Treating Cancer with an Antibody and Intravenous Administration of a Recombinant MVA
RU2795103C2 (ru) Комбинированная терапия для лечения рака путем внутривенного введения рекомбинантного mva и антитела
CA3240596A1 (en) Therapy for modulating immune response with recombinant mva encoding il-12